期刊文献+

血脂康治疗2型糖尿病高血脂症的系统评价 被引量:4

Systematic Review on Xuezhikang in the Treatment of Type 2 Diabetes with Hyperlipoidemia
原文传递
导出
摘要 目的:系统评价血脂康治疗2型糖尿病高血脂症的疗效。方法:计算机检索Cochrane图书馆和PubMed、EMBASE、CBM、VIP、CNKI数据库,手工检索相关文献,按纳入与排除标准选择试验、评价质量、提取资料,并用RevMan5.0软件对数据进行Meta分析。结果:共纳入血脂康治疗2型糖尿病高血脂症的6个随机对照试验,Meta分析结果显示,试验组与对照组中总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、空腹血糖、餐后2h血糖、糖化血红蛋白、24h尿白蛋白排除率等指标的改善组间差异有统计学意义(P<0.05)。结论:本系统评价结果初步显示,常规降糖治疗+血脂康治疗2型糖尿病高血脂症的疗效优于常规降糖治疗。但由于纳入研究较少,研究质量普遍不高,上述结果有待高质量、大样本的随机双盲对照试验加以验证。 OBJECTIVE: To evaluate the efficacy of Xuezhikang in the treatment of type 2 diabetes with hypedipoidemia. METHODS: Retrieved from Cochrane Library, PubMed, EMBASE, CBM, VIP and CNKI databases and related periodicals, included randomized controlled trails (RCTs) was evaluated in quality. Meta-analysis was conducted with RevMan 5.0 software. RESULTS: The meta-analysis of 6 included RCT showed that the improvement of TC, TG, LDL-C, HDL-C, FBS, 2 h-BS, HbAlc, UAE in trial group were different from control group. There was statistical significance in difference between 2 groups. CONCLUSION: Routine glycemic control combined with Xuezhikang has better effect than routine glycemic control in the treatment of type 2 diabetes with hyperlipoidemia. Because the number and quality of included study are not satisfactory, the study result should be confirmed by randomized double-blind controlled trial.
出处 《中国药房》 CAS CSCD 北大核心 2010年第12期1106-1109,共4页 China Pharmacy
关键词 血脂康 2型糖尿病 高血脂 系统评价 META分析 Xuezhikang Type 2 diabetes Hyperlipoidemia Systematic review Meta-analysis
  • 引文网络
  • 相关文献

参考文献9

二级参考文献44

共引文献64

同被引文献155

引证文献4

二级引证文献190

;
使用帮助 返回顶部